Delving into the Latest Updates on CV-0801(GlaxoSmithKline) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, mRNA vaccine

Synonyms

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

GSK Plc

Active Organization

CureVac NV

GSK Plc

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will compare the investigational vaccines to control vaccine.
The purpose of Part B of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will compare the investigational vaccine under three different storage conditions.

Start Date01 Aug 2023

Sponsor / Collaborator

GSK Plc

[+1]

100 Clinical Results associated with CV-0801(GlaxoSmithKline)

Login to view more data

100 Translational Medicine associated with CV-0801(GlaxoSmithKline)

Login to view more data

100 Patents (Medical) associated with CV-0801(GlaxoSmithKline)

Login to view more data

100 Deals associated with CV-0801(GlaxoSmithKline)

Login to view more data